New Cambridge office will help Cubresa accelerate pace in developing preclinical imaging devices

Cambridge MA – April 7, 2015 – To help researchers understand diseases that are difficult to diagnose like cancer and Alzheimer’s, an innovative Canadian preclinical imaging device company known as Cubresa has immersed itself in the intellectually-rich Massachusetts life sciences sector by opening the doors of its U.S. office in the Cambridge Innovation Center.

Cambridge Mayor David Maher (center) with Co-Founder of Canadian Technology Accelerator and Trade Commissioner of Life Sciences Business Development at the Consulate General of Canada Christine Sarkisian (left), Cubresa Founder James Schellenberg (second from left), MLSC Vice President for Communications & Marketing Angus McQuilken (second from right) and Manager of Business Development at Cubresa Helena Mistry (right).

Cambridge Mayor David Maher (center) with Co-Founder of Canadian Technology Accelerator and Trade Commissioner of Life Sciences Business Development at the Consulate General of Canada Christine Sarkisian (left), Cubresa Founder James Schellenberg (second from left), MLSC Vice President for Communications & Marketing Angus McQuilken (second from right) and Manager of Business Development at Cubresa Helena Mistry (right).

“Massachusetts’ flourishing life sciences community has become a magnet for international companies that want to be where the action is, including companies from Canada,” said Governor Charlie Baker. “We welcome Cubresa, and look forward to partnering with them to create jobs, and to further strengthen the growing ties between our regions.”

“To provide researchers with the best imaging technology, we’ve got to be surrounded by world leaders in life science innovations,” said James Schellenberg, Founder of Cubresa Inc., headquartered in Winnipeg, Canada. “In Cambridge, we will be in an environment that will help us lead the way in developing preclinical devices that will, in turn, help researchers better understand complex diseases and develop personalized therapies.”

With over 35 million suffering from Alzheimer’s worldwide, Schellenberg said this is just one example why advancements in preclinical instrumentation capable of characterizing the disease are critical. At present, the only way to definitively diagnose Alzheimer’s is after a person dies.

“Partnering with Cubresa puts the City of Cambridge at the leading edge of life science research and manufacturing,” said Cambridge Mayor David Maher. “The addition of Cubresa enhances our community’s reputation as the place to be for life science companies, with some of the brightest minds in the United States, and now, Canada. I want to welcome them to our growing family here in Cambridge and congratulate them on their progress in the fight against Alzheimer’s disease.”

 

Adding congratulations to Cubresa is Susan Windham Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center, the agency charged with implementing the state’s 10-year, $1 billion Life Sciences Initiative.

“On behalf of the Center, I would like to extend a warm welcome to the team at Cubresa as the company opens its first U.S facility here in Massachusetts,” said Susan Windham Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center. “Cubresa’s molecular imaging technology will be a valued addition to our life sciences ecosystem and we appreciate management’s decision to locate in Massachusetts. We look forward to partnering with Cubresa and extend our best wishes for its continued growth and success.”

Among its innovations, Cubresa Inc. builds compact preclinical nuclear imaging scanners for conducting cutting edge drug and disease research.

Already underway in Canada is use of its latest high tech device in Halifax where researchers are evaluating new diagnostic methods in mice to help solve the mystery of one of the world’s most difficult to diagnose diseases – Alzheimer’s.

This announcement is not intended to be a commercial endorsement by the MLSC of any products or services provided or developed by the entities referenced in this release.

About Cubresa Inc.
Cubresa, a privately held corporation headquartered in Winnipeg, Manitoba, CANADA, markets preclinical molecular imaging solutions, empowering researchers to better understand complex diseases and develop personalized therapies. For more information on Cubresa, please visit: www.cubresa.com

About Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, $1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation’s most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. For more information, visit www.masslifesciences.com.

Media Contact:
Michael Simpson
Director of Marketing
Cubresa Inc.
204.272.2409
msimpson@cub2017.azurewebsites.net

Media Contact:
Angus G. McQuilken
Vice President for Communications & Marketing
Massachusetts Life Sciences Center
617.921.7749